Using CRISPR-Cas9 to knockout the A2A receptor in Her2-targeting CAR-T cells, Giuffrida et al. showed the modification increased transcription of pro-inflammatory cytokines and improve anti-tumor efficacy in in vivo breast cancer models [98]. This evidence concerns the gene ERBB2 and breast carcinoma.